And in case you missed it, here is her second, equally impressive second preprint.
www.biorxiv.org/content/10.1...
@kislingerthomas.bsky.social
Senior Scientist at Princess Margaret Cancer Centre, Toronto, Canada π¨π¦ Clinical proteomics, liquid biopsies and cell surface markers
And in case you missed it, here is her second, equally impressive second preprint.
www.biorxiv.org/content/10.1...
Latest preprint from the lab. Great work as always by Meinusha. This is the last chapter for her PhD.
www.biorxiv.org/content/10.1...
Interestingly, the urinary proteome of Black patients harboured more features of aggressive cancers than those of grade- and PSA-matched White patients. These observations highlight the importance of controlling for ancestry-associated differences in biomarker development.
20.08.2025 14:08 β π 0 π 0 π¬ 0 π 0This cohort was stratified by ancestry β thought to be a risk-factor for aggressive disease. We found surprisingly large differences and dysregulation of immune pathways.
20.08.2025 14:08 β π 0 π 0 π¬ 1 π 0After nearly 15 years of urine proteomics of prostate cancer patients, this is our most comprehensive work to date. We generated spectral libraries from hundreds of samples to rapidly analyze 329 post-DRE urines.
20.08.2025 14:08 β π 0 π 0 π¬ 1 π 0Checkout our latest pre-print
www.biorxiv.org/content/10.1...
Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity: Cell Reports www.cell.com/cell-reports...
01.07.2025 16:50 β π 2 π 0 π¬ 0 π 0βͺcheckout our latest paper in @natbiotech.nature.com . We developed a graph-based algorithm that comprehensively generates non-canonical peptides in linear time. www.nature.com/articles/s41...
16.06.2025 19:09 β π 15 π 1 π¬ 0 π 0Identification of non-canonical peptides with moPepGen - @uclahealth.org @uoftmedicine.bsky.social @kislingerthomas.bsky.social go.nature.com/3HYJyyz
16.06.2025 14:38 β π 15 π 5 π¬ 2 π 0New collaborative work from PhD student Aastha. Using proteomics for CSF-based biomarker discovery
pubmed.ncbi.nlm.nih.gov/40321620/
New review from our team.
pubmed.ncbi.nlm.nih.gov/40227112/
I am everywhere and nowhere π»
11.03.2025 21:07 β π 1 π 0 π¬ 0 π 0Last paper for 2024. Nice work by PDF Matt Waas on proteomics of HNSCC tissues to identify novel biomarkers within the N0 population. Great collaboration with Laurie Ailles
and support from many colleagues Princess Margaret Cancer Centre
Definitely also expressed in skin.
15.12.2024 19:03 β π 0 π 0 π¬ 0 π 0It gets upregulated in squamous carcinomas and is required for growth and survival
15.12.2024 18:12 β π 2 π 0 π¬ 1 π 0There is expression in the cerebellum for sure.
Might be through that route
Not sure how it gets into milk. Maybe low level expression in some mammary epithelial populations. I will look at our own CSF, urine and normal mammary populations tomorrow.
Actually most datasets correlate reasonable well for Fat2. Since I have worked on this protein for the last 8 years
15.12.2024 17:12 β π 0 π 0 π¬ 1 π 0Let us know your thoughts
15.12.2024 15:03 β π 0 π 0 π¬ 0 π 0Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers https://www.biorxiv.org/content/10.1101/2024.12.11.627962v1
14.12.2024 14:48 β π 1 π 1 π¬ 0 π 0Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers https://www.biorxiv.org/content/10.1101/2024.12.11.627962v1
14.12.2024 14:48 β π 3 π 2 π¬ 0 π 0As mentioned a large number of colleagues contributed to this work, most importantly the project was led by a fantastic PhD student Meinusha Govindarajan and a research associate Salvador Mejia-Guerrero.
14.12.2024 16:38 β π 2 π 0 π¬ 0 π 0The entire data will be evaluable as a searchable web-interface (Glyco PDXplorer).
14.12.2024 16:38 β π 1 π 0 π¬ 1 π 0Fat2 deletion leads to regulation of surface architecture and integrin-PI3K signaling. Finally we raise a highly specific Fat2 antibody which we repurposed into a CAR T construct for proof-of-concept preclinical evaluation.
14.12.2024 16:38 β π 1 π 0 π¬ 1 π 0We discover Fat2 as a novel head and neck cancer surface antigen that has minimal expression in normal human tissues, is essential for tumour grown in vitro and in vivo and high expression is associated with poor survival
14.12.2024 16:38 β π 1 π 0 π¬ 1 π 0We developed a discovery pipeline that utilizes N-glycoproteomics in PDX models to discover novel cancer specific surface antigenes. We initially focus on head and neck cancers and combine our data with patient tumours and cell surface capture
14.12.2024 16:38 β π 3 π 1 π¬ 1 π 0Big effort (> 7 years) from a large number of colleagues. Finally on BioRxiv and to be submitted in January
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
www.biorxiv.org/content/10.1...
Very nice!
13.12.2024 20:47 β π 0 π 0 π¬ 0 π 0